Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes.
Diabetes
Inflammation
Leukotrienes
Lipids
Lipoxins
Prostaglandins
Resolvins
Specialized pro-resolving mediators
Tuberculosis
Journal
Prostaglandins & other lipid mediators
ISSN: 1098-8823
Titre abrégé: Prostaglandins Other Lipid Mediat
Pays: United States
ID NLM: 9808648
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
10
06
2019
revised:
31
10
2019
accepted:
08
11
2019
pubmed:
15
11
2019
medline:
10
4
2021
entrez:
15
11
2019
Statut:
ppublish
Résumé
Individuals with concurrent tuberculosis (TB) and Type 2 diabetes (DM) have a higher risk of adverse outcomes. To better understand potential immunological differences, we utilized a comprehensive panel to characterize pro-inflammatory and pro-resolving (i.e., mediators involved in the resolution of inflammation) lipid mediators in individuals with TB and TB-DM. A nested cross-sectional study of 40 individuals (20 newly diagnosed DM and 20 without DM) was conducted within a cohort of individuals with active drug-susceptible treatment-naïve pulmonary TB. Lipid mediators were quantified in serum samples through lipid mediator profiling. We conducted correlation-based analysis of these mediators. Overall, the arachidonic acid-derived leukotriene and prostaglandin families were the most abundant pro-inflammatory lipid mediators, while lipoxins and maresins families were the most abundant pro-resolving lipid mediators in individuals with TB and TB-DM. Individuals with TB-DM had increased correlations and connectivity with both pro-inflammatory and pro-resolving lipid mediators compared to those with TB alone. We identified the most abundant lipid mediator metabolomes in circulation among individuals with TB and TB-DM; in addition, our data shows a substantial number of significant correlations between both pro-inflammatory and pro-resolving lipid mediators in individuals with TB-DM, delineating a molecular balance that potentially defines this comorbidity.
Identifiants
pubmed: 31726221
pii: S1098-8823(19)30149-2
doi: 10.1016/j.prostaglandins.2019.106398
pmc: PMC7067657
mid: NIHMS1543500
pii:
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Leukotrienes
0
Lipoxins
0
Prostaglandins
0
Docosahexaenoic Acids
25167-62-8
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106398Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069465
Pays : United States
Organisme : Wellcome Trust
ID : 107613/Z/15/Z
Pays : United Kingdom
Organisme : FIC NIH HHS
ID : D43 TW009574
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI115940
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI097494
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Organisme : NICHD NIH HHS
ID : R00 HD089753
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069465
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None declared.
Références
Semin Immunol. 2015 May;27(3):200-15
pubmed: 25857211
Nat Rev Immunol. 2016 Jan;16(1):51-67
pubmed: 26688348
Sci Rep. 2017 Jun 28;7(1):4334
pubmed: 28659627
EBioMedicine. 2016 Jan 14;4:115-23
pubmed: 26981576
FASEB J. 2019 Nov;33(11):13028-13039
pubmed: 31500466
PLoS One. 2014 Oct 15;9(10):e108854
pubmed: 25329995
Sci Signal. 2015 Jan 27;8(361):ra10
pubmed: 25628460
PLoS One. 2014 Nov 13;9(11):e112108
pubmed: 25393696
Nat Med. 2015 Sep;21(9):1071-5
pubmed: 26236990
J Infect Dis. 2016 Dec 1;214(11):1629-1637
pubmed: 27630197
PLoS Med. 2008 Jul 15;5(7):e152
pubmed: 18630984
Methods Mol Biol. 2018;1730:59-72
pubmed: 29363065
Cell. 2010 Mar 5;140(5):717-30
pubmed: 20211140
J Clin Invest. 2005 Jun;115(6):1601-6
pubmed: 15931391
BMC Infect Dis. 2016 Aug 05;16:368
pubmed: 27494953
Malar J. 2013 Feb 21;12:69
pubmed: 23433077
Cell. 2012 Feb 3;148(3):434-46
pubmed: 22304914
Chest. 2017 Jul;152(1):174-180
pubmed: 28434937
Expert Opin Med Diagn. 2013 Jan;7(1):37-51
pubmed: 23335946
Chest. 2016 Jun;149(6):1501-8
pubmed: 26973015
Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C39-54
pubmed: 24696140
Clin Infect Dis. 2008 Sep 1;47(5):634-41
pubmed: 18652554
Nature. 2014 Jul 3;511(7507):99-103
pubmed: 24990750
Ann Am Thorac Soc. 2013 Oct;10(5):441-9
pubmed: 23987505
Immunol Rev. 2015 Mar;264(1):264-75
pubmed: 25703565
Diabetes Care. 2013 Jun;36(6):1629-34
pubmed: 23321217
Tuberculosis (Edinb). 2018 Dec;113:153-162
pubmed: 30514497
Cell Host Microbe. 2010 Mar 18;7(3):177-9
pubmed: 20227659
N Engl J Med. 2014 Oct 2;371(14):1354-6
pubmed: 25271609
Sci Rep. 2017 May 17;7(1):1999
pubmed: 28515464
Tuberculosis (Edinb). 2016 Dec;101S:S124-S134
pubmed: 27733244
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Dec;1863(12):1511-1522
pubmed: 30308322
Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1280-1287
pubmed: 29297449
Prostaglandins Leukot Essent Fatty Acids. 2018 Jun;133:29-34
pubmed: 29789130
Crit Care Med. 2017 Jan;45(1):58-68
pubmed: 27632672
Bull World Health Organ. 2011 May 1;89(5):352-9
pubmed: 21556303
PLoS One. 2016 Feb 16;11(2):e0149319
pubmed: 26881986
Cell Rep. 2017 Sep 26;20(13):3162-3175
pubmed: 28954232
Sci Rep. 2016 Sep 06;6:32619
pubmed: 27595802
PLoS One. 2016 Jan 11;11(1):e0146876
pubmed: 26752596
Diabetes. 2016 Dec;65(12):3718-3729
pubmed: 27605625
Chest. 2017 Jul;152(1):165-173
pubmed: 28434936
PLoS Med. 2016 Aug 09;13(8):e1002072
pubmed: 27505150
BMC Med. 2018 Sep 24;16(1):161
pubmed: 30244671
PLoS Pathog. 2014 Oct 02;10(10):e1004433
pubmed: 25275318
Biochem Biophys Res Commun. 2018 Oct 20;505(1):29-35
pubmed: 30236987
Elife. 2018 Feb 27;7:
pubmed: 29482717